{"title":"深入了解 Janus 激酶的特异性:从分子结构到癌症疗法","authors":"Tian-Hua Wei, Meng-Yi Lu, Si-Hui Yao, Yu-Qi Hong, Jin Yang, Meng-Yuan Zhang, Yu-Qi Yin, Yu-Jie Han, Qing-Qing Li, Zi-Xuan Wang, Yi-Bo Wang, Zhen-Jiang Tong, Yun Zhou, Wei-Chen Dai, Yan-Cheng Yu, Shan-Liang Sun, Ye Yang, Nian-Guang Li, Zhi-Hao Shi","doi":"10.1002/mog2.69","DOIUrl":null,"url":null,"abstract":"<p>Janus Kinases (JAKs) play a crucial role as therapeutic targets for various cancers. However, the current JAK inhibitors (JAKi) available have limited therapeutic benefits due to their lack of selectivity. This review focuses on the structural analysis to elucidate the molecular determinants of JAKs specificity and the discovery and design of selective JAKi. It includes descriptions and comparison of different JAK structures and their binding sites, a comparative analysis of JAKi and their binding modes, detailed interaction fingerprints (IFPs), and an extensive structure-selectivity relationship (SSRs). Moreover, the review also explores the challenges and possibilities of using computational structure-based methods for discovering and designing selective JAKi. Other structure-based approaches, such as targeting the pseudokinase domain, as well as covalent and allosteric designs, are also covered. Based on this analysis, key determinants corresponding to JAK specificity and rational medicinal chemistry strategies are proposed to facilitate the development of highly selective JAKi. Overall, we aim to enhance the understanding of JAK specificity and explore strategies that can lead to the discovery of effective and selective JAKi in cancer therapy, thus improving the prognosis for cancer patients.</p>","PeriodicalId":100902,"journal":{"name":"MedComm – Oncology","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.69","citationCount":"0","resultStr":"{\"title\":\"Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics\",\"authors\":\"Tian-Hua Wei, Meng-Yi Lu, Si-Hui Yao, Yu-Qi Hong, Jin Yang, Meng-Yuan Zhang, Yu-Qi Yin, Yu-Jie Han, Qing-Qing Li, Zi-Xuan Wang, Yi-Bo Wang, Zhen-Jiang Tong, Yun Zhou, Wei-Chen Dai, Yan-Cheng Yu, Shan-Liang Sun, Ye Yang, Nian-Guang Li, Zhi-Hao Shi\",\"doi\":\"10.1002/mog2.69\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Janus Kinases (JAKs) play a crucial role as therapeutic targets for various cancers. However, the current JAK inhibitors (JAKi) available have limited therapeutic benefits due to their lack of selectivity. This review focuses on the structural analysis to elucidate the molecular determinants of JAKs specificity and the discovery and design of selective JAKi. It includes descriptions and comparison of different JAK structures and their binding sites, a comparative analysis of JAKi and their binding modes, detailed interaction fingerprints (IFPs), and an extensive structure-selectivity relationship (SSRs). Moreover, the review also explores the challenges and possibilities of using computational structure-based methods for discovering and designing selective JAKi. Other structure-based approaches, such as targeting the pseudokinase domain, as well as covalent and allosteric designs, are also covered. Based on this analysis, key determinants corresponding to JAK specificity and rational medicinal chemistry strategies are proposed to facilitate the development of highly selective JAKi. Overall, we aim to enhance the understanding of JAK specificity and explore strategies that can lead to the discovery of effective and selective JAKi in cancer therapy, thus improving the prognosis for cancer patients.</p>\",\"PeriodicalId\":100902,\"journal\":{\"name\":\"MedComm – Oncology\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mog2.69\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedComm – Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mog2.69\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm – Oncology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mog2.69","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Janus 激酶(JAKs)作为各种癌症的治疗靶点发挥着至关重要的作用。然而,目前可用的 JAK 抑制剂(JAKi)由于缺乏选择性,治疗效果有限。本综述侧重于通过结构分析来阐明 JAKs 特异性的分子决定因素,以及选择性 JAKi 的发现和设计。它包括不同 JAK 结构及其结合位点的描述和比较、JAKi 及其结合模式的比较分析、详细的相互作用指纹图谱(IFP)以及广泛的结构选择性关系(SSR)。此外,该综述还探讨了使用基于计算结构的方法发现和设计选择性 JAKi 所面临的挑战和可能性。其他基于结构的方法,如靶向伪激酶结构域,以及共价和异构设计,也包括在内。在此分析的基础上,提出了与 JAK 特异性相对应的关键决定因素和合理的药物化学策略,以促进高选择性 JAKi 的开发。总之,我们的目标是加深对 JAK 特异性的理解,并探索在癌症治疗中发现有效和选择性 JAKi 的策略,从而改善癌症患者的预后。
Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics
Janus Kinases (JAKs) play a crucial role as therapeutic targets for various cancers. However, the current JAK inhibitors (JAKi) available have limited therapeutic benefits due to their lack of selectivity. This review focuses on the structural analysis to elucidate the molecular determinants of JAKs specificity and the discovery and design of selective JAKi. It includes descriptions and comparison of different JAK structures and their binding sites, a comparative analysis of JAKi and their binding modes, detailed interaction fingerprints (IFPs), and an extensive structure-selectivity relationship (SSRs). Moreover, the review also explores the challenges and possibilities of using computational structure-based methods for discovering and designing selective JAKi. Other structure-based approaches, such as targeting the pseudokinase domain, as well as covalent and allosteric designs, are also covered. Based on this analysis, key determinants corresponding to JAK specificity and rational medicinal chemistry strategies are proposed to facilitate the development of highly selective JAKi. Overall, we aim to enhance the understanding of JAK specificity and explore strategies that can lead to the discovery of effective and selective JAKi in cancer therapy, thus improving the prognosis for cancer patients.